Achieve Life Sciences, Inc. (ACHV) financial statements (2021 and earlier)

Company profile

Business Address 520 PIKE STREET
SEATTLE, WA 98101
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3617155265547
Cash and cash equivalents3617105153428
Short-term investments  5 102119
Other undisclosed cash, cash equivalents, and short-term investments 0(0) 000
Restricted cash and investments   0  0
Receivables 000106
Prepaid expense 110   
Other current assets      0
Other undisclosed current assets1(0)0 122
Total current assets:3717166275756
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0000010
Intangible assets, net (including goodwill)3334   
Goodwill1111   
Intangible assets, net (excluding goodwill)2223   
Restricted cash and investments000000 
Other noncurrent assets0000000
Total noncurrent assets:3444111
TOTAL ASSETS:40211910275856
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2221532
Accounts payable0100210
Accrued liabilities1010211
Employee-related liabilities1110011
Debt 000000
Deferred revenue and credits  5 
Other undisclosed current liabilities101141220
Total current liabilities:333282122
Noncurrent Liabilities
Long-term debt and lease obligation000 000
Capital lease obligations0 000
Operating lease, liability00
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities:000 000
Total liabilities:333292122
Stockholders' equity
Stockholders' equity attributable to parent, including:3718168193734
Common stock0000000
Additional paid in capital98644121213212191
Accumulated other comprehensive income0000333
Accumulated deficit(60)(46)(25)(13)(197)(177)(160)
Warrants and rights outstanding      3
Other undisclosed stockholders' equity attributable to parent      (3)
Total stockholders' equity:3718168193734
TOTAL LIABILITIES AND EQUITY:40211910275856

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues
(Revenue, Net)
    5  
Cost of revenue    (1)  
Gross profit:    4  
Operating expenses(15)(17)(13)(7)(25)(37)(57)
Operating loss:(15)(17)(13)(7)(21)(37)(57)
Nonoperating income (expense)000(7)123
Investment income, nonoperating0001000
Other nonoperating expense(0)(0)(0)(0)(0)(0)(0)
Loss from continuing operations before income taxes:(15)(16)(13)(14)(20)(35)(54)
Income tax benefit   3   
Loss before gain (loss) on sale of properties:(15)(16)(13)(11)(20)(35)(54)
Other undisclosed net income0      
Net loss:(15)(16)(13)(11)(20)(35)(54)
Other undisclosed net income attributable to parent     1827
Net loss available to common stockholders, diluted:(15)(16)(13)(11)(20)(17)(26)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(15)(16)(13)(11)(20)(35)(54)
Other comprehensive income (loss)  (0) 00(0)
Comprehensive loss:(15)(16)(13)(11)(20)(35)(54)
Other undisclosed comprehensive income, net of tax, attributable to parent  0  1827
Comprehensive loss, net of tax, attributable to parent:(15)(16)(13)(11)(20)(17)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: